Latest updates for Disease Modifying Therapies (Dmt)

Fresh curated links around Disease modifying therapies (DMT) are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Recent items include:

  • Early high-efficacy MS drugs cut relapse risk, not progression
  • Do nothing neuros maybe harming your brains
  • Treatments (Part 8) Who isn’t using anti-CD20 depleting antibodies?

Post angles to try

Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

multiplesclerosisnewstoday.com /2 weeks ago

Early high-efficacy MS drugs cut relapse risk, not progression

Early treatment with high-efficacy disease-modifying therapies (DMTs) lowered the risk of relapse-associated disability progression in people with multiple sclerosis (MS), but had...

Read source
multiple-sclerosis-research.org /1 month ago

Do nothing neuros maybe harming your brains

Daruwalla et al. Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis. Brain. 2026 Jul 24:awag252. Clinically silent MRI lesions occur...

Read source
multiple-sclerosis-research.org /1 month ago

Treatments (Part 8) Who isn’t using anti-CD20 depleting antibodies?

The MS world is changing and the advent of anti-CD20 depleting antibodies has allowed this to happen. For many years you had to get rid of T cells to control MS and that would give...

Read source
multiple-sclerosis-research.org /1 month ago

The fumarates compared to anti-CD20s 2025-2026 (Part 11)

I’ve done natalizumab, alemtuzumab, anti-CD20 and cladribine use, now is the time to look at the laggards. Where are the lower efficacy treatments being used. Don’t get me wrong th...

Read source
multiple-sclerosis-research.org /3 weeks ago

HE SC DMTs

Following on from the post on subcutaneous ofatumumab and intravenous ocrelizumab we had a question. “Is the Subcut version of Tysabri as effective as the infusion based on the cur...

Read source
multiple-sclerosis-research.org /1 month ago

Dimethyl fumarate and Progression

Dann J, Klöster K, Ceylan U, Heitmann N, Eggers B, Rozanova S, Eisenacher M, Marcus-Alic K, Winklhofer KF, Gold R, Faissner S. Monomethyl Fumarate Modulates Iron Metabolism and Mit...

Read source
multiple-sclerosis-research.org /2 weeks ago

CD20 is an IRT when will they twig?

Maal AB, Arki MK, Nabavi SM, Rezaei-Tavirani M, Rismani E, Vosough M, Azizi G, Hossein-Khannazer N. Immune reconstitution and tolerance-inducing therapies as promising therapeutic...

Read source
multiplesclerosisnewstoday.com /1 week ago

Experimental MS drug bests approved therapy in cutting relapses in 2 trials

An experimental oral drug called remibrutinib outperformed the approved therapy Aubagio (teriflunomide) in reducing disease flare rates in two large, late-stage clinical trials inv...

Read source
multiple-sclerosis-research.org /1 month ago

Stopping treatment with an anti-relapse agent in progressive MS. What does it tell us?

Ocrelizumab is licenced for relapsing and active primary progressive MS (Lesions and relapses) in the EU…It is active because we know it works by stopping B cells from entering the...

Read source
multiple-sclerosis-research.org /1 month ago

Learning about what could happen in MS by looking at other conditions

In MS we do not know of a definative target. But in neuromyelitis optic a demyelinating condition of the spinal cord and optic nerves is associated with antibodies against a water...

Read source
multiplesclerosisnewstoday.com /3 weeks ago

One silent MRI lesion may be enough to consider stronger MS treatment

People with relapsing-remitting multiple sclerosis (RRMS) who show even a single silent lesion on an MRI scan while taking a lower- or moderate-efficacy disease-modifying therapy (...

Read source
multiplesclerosisnewstoday.com /5 days ago

New MS cell therapy safely retrains immune system to tolerate myelin

A new experimental cell therapy that pairs a patient’s own red blood cells with myelin protein fragments safely calmed the immune system and helped dampen the inflammatory attack t...

Read source
multiple-sclerosis-research.org /3 weeks ago

Genomics and anti-CD20 depleting antibodies

There are lots of different B cell depleting antibodies used in cancer and autoimmunity. There are three approved for MS (in blue below. Ublituximab, ocrelizumab and ofatumumab), b...

Read source
multiple-sclerosis-research.org /1 month ago

New remyelination drug…Will it make it

Yang Y, Bai B, Knutsen LJS, Hamlyn RJ, Cui QL, Antel J, Macklin W, Medicetty S, Trapp BD. A novel small molecule remyelination therapy for multiple sclerosis. NPJ Drug Discov. 2026...

Read source
medicalxpress.com /1 month ago

Bloodstream-delivered cell therapy slows muscle decline in young people with Duchenne muscular dystrophy, trial finds

A cell therapy called deramiocel could slow muscle weakening in boys and young men with advanced Duchenne muscular dystrophy (DMD) and may also slow heart damage in those who alrea...

Read source
multiple-sclerosis-research.org /1 month ago

Anti-CD20 depleting antibodies. What did you find? (Part 9)

So rather than about 100 people using alemtuzumab, it is about 20,000 people recieving an anti-CD20. Remember this is an underestimate. Also the data has not been repeated I have e...

Read source
multiple-sclerosis-research.org /1 week ago

Where is the action of anti-CD20 and other antibodies on Neurodegeneration

Nerve damage is a consequence of poorly controlled MS and in one place it is easy to monitor nerve damage and this is in the eye. The eye is connected to your brain and nerve damag...

Read source
multiplesclerosisnewstoday.com /2 weeks ago

Large study shows how 2 MS treatments stack up in the real world

Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) are both highly effective at preventing relapses and disability worsening in people with relapsing-remitting multiple sclerosis (RRM...

Read source
hemophilianewstoday.com /4 weeks ago

Gene and Disease-Modifying Therapies for Hemophilia

Inside the evolving hemophilia treatment landscape, including AAV-based gene therapies, non-factor prophylaxis, and approaches that aim to reduce treatment burden. The post Gene an...

Read source
healio.com /3 weeks ago

Duvakitug shows improved outcomes in ulcerative colitis, Crohn’s

An investigational anti-TL1A monoclonal antibody achieved “clinically meaningful” outcomes compared with placebo in patients with inflammatory bowel disease, according to results o...

Read source
multiple-sclerosis-research.org /2 weeks ago

Comparing anti-CD20 antibodies. Is ofatumumab the same as ocrelizuamb?

The answer to this is unlikely to occur from a proper clinical trial done by pharma as it would be dangerous if there is a difference and one seems better than the other. MSBase is...

Read source
multiple-sclerosis-research.org /4 weeks ago

Magnifying Cladribine in year 3-4

ProfK has ben magnifying the cladribine natural history and they have got back to where we left off in 2010, when they threw cladribine out with the bath water. They say that cladr...

Read source
multiplesclerosisnewstoday.com /3 weeks ago

Stroke drug may ease MS damage, animal studies suggest

A drug used to prevent stroke complications may help preserve myelin, the protective coating around nerve fibers that is damaged in multiple sclerosis (MS), according to a review o...

Read source
multiple-sclerosis-research.org /2 weeks ago

To be precise: Anti-CD20 Tx

What does a personalised biomarker in anti-CD20 therapy need to measure? CoI: None.

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.

Start creating posts

Sources covering Disease Modifying Therapies (Dmt)

hemophilianewstoday.com

Recent coverage from public sources
Public source

medicalxpress.com

Recent coverage from public sources
Public source

multiple-sclerosis-research.org

Recent coverage from public sources
Public source

multiplesclerosisnewstoday.com

Recent coverage from public sources
Public source

healio.com

Recent coverage from public sources
Public source

Related searches

Archive News Experimental treatment Disease modifying therapies (DMT) Kesimpta MRI MS relapse Ocrevus RRMS clinical trials disease progression myelin

Recent searches

Artificial Intelligence Machine Learning Data Science Data Engineering Business Intelligence Web Development Software Development Software Testing Programming JavaScript DevOps Cyber Security Product Management Project Management Design UX UX Research Graphic Design Video Production Video Editing